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The antiapoptotic effect of melatonin (MEL) has been de-
scribed in several systems. In particular, MEL inhibits glu-
cocorticoid-mediated apoptosis. Our group previously dem-
onstrated that in the thymus, MEL inhibits the release of
Cytochrome C from mitochondria and the dexamethasone-
dependent increase of bax mRNA levels. In this study we an-
alyzed the ability of MEL to regulate the activation of the
glucocorticoid receptor (GR) in mouse thymocytes. We found
that even though the methoxyindole does not affect the ligand
binding capacity of the receptor, it impairs the steroid-de-
pendent nuclear translocation of the GR and also prevents
transformation by blocking the dissociation of the 90-kDa
heat shock protein. Coincubation of the methoxyindole with
dexamethasone did not affect the expression of a reporter
gene in GR-transfected Cos-7 cells or HC11 and L929 mouse
cell lines that express Mel-1a and retinoid-related orphan re-
ceptor- (ROR) receptors. Therefore, the antagonistic effect
of MEL seems to be specific for thymocytes, in a Mel 1a- and
ROR-independent manner. In summary, the present results
suggest a novel mechanism for the antagonistic action of MEL
on GR-mediated effects, which involves the inhibition of 90-
kDa heat shock protein dissociation and the cytoplasmic re-
tention of the GR. (Endocrinology 147: 5452–5459, 2006)
IT HAS BEEN demonstrated that melatonin (MEL), a nat-ural compound synthesized in a variety of organs, is a
cell-protective agent (for a review see Refs 1, 2). The anti-
apoptotic activity of MEL was previously described in sev-
eral systems such as immune cells (3–5), cerebellar neurons
(6), and rat brain astrocytes (7).
Apoptosis is a complex process controlled by external
signals and also an internal genetic program involved in
the regulation of homeostasis and the proper functioning
of tissues and organs. Several diseases as cancer, autoim-
munity, persistent infections, and neurodegeneration have
been ascribed to a failure in the apoptotic program (8 –10).
In this sense, malfunction of the death machinery resulting
from the mutations of genes that code for proteins in-
volved in the apoptotic program has been reported, i.e. the
p53, an executioner of DNA damage triggered apoptosis,
and Bax, a proapoptotic molecule with the ability to per-
turb mitochondrial membrane integrity, are frequently
mutated in malignant neoplasms (8). Antiapoptotic pro-
teins like bcl-2, cellular-inhibitor of apoptosis protein 2,
and neuronal apoptosis inhibitory protein 1 are often al-
tered in follicular lymphomas (9).
The thymus is a well-known model for apoptosis studies.
It has been demonstrated that not only the chronic admin-
istration of MEL but also the coincubation of the methoxy-
indole with dexamethasone (DEX) reduce the glucocorticoid-
induced programed cell death in thymocytes (5, 11). In that
sense, our group demonstrated that MEL inhibits apoptosis
by preventing cytochrome C release and reducing the glu-
cocorticoid mediated-increase in Bax levels.
The mechanisms whereby MEL influences apoptosis have
not been clarified yet, although different options have been
suggested. There are at least four possible scenarios to ex-
plain its biological effects: 1) its antioxidant properties as
scavenger of free radicals (12–15) and/or its specific inter-
action with 2) the plasma membrane receptors (16–19), 3)
nuclear receptors (20–23), and 4) Ca2 binding proteins such
as calmodulin (24–26). In a previous work (5), we suggested
that the antiapoptotic effect of MEL in thymocytes could be
due to the interaction of the methoxyindole with specific
receptors. The presence of MEL membrane receptors (Mel 1a)
has been described in rat T and B lymphocytes (18). On the
other hand, it is known that MEL is a natural ligand of
retinoid Z receptor (RZR) and RZR, two members of ROR,
retinoid-related orphan receptor (ROR) family. Through
these receptors, melatonin regulates the expression of several
genes, i.e. the down-regulation of 5-lipoxygenase expression,
mediated by RZR receptor in B lymphocytes (27, 28). MEL
also binds to purified thymocyte nuclei (29), suggesting the
existence of functional ROR family receptors in the thymus.
Inhibition of the glucocorticoid receptor-dependent gene
expression by MEL was described by Persengiev (30), who
reported that the inhibition of glucocorticoid receptor (GR)
transcriptional activity of a mouse mammary tumor virus
(MMTV) promoter construct was dependent on the coex-
pression of both MEL receptor Mel 1a and GR.
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Because MEL is capable of preventing DEX-induced gene
expression, it seems possible that the methoxyindole could
control the ability of the activated GR to reach their specific
target promoters.
The activation of GR involves several structural alterations
occurring in its ligand binding domain. These changes are
translated to the receptor surface including the DNA binding
site. As a consequence, those modifications allow the GR
interaction with specific glucocorticoid response elements
(GREs) of target genes. Thus, the antagonistic effect of a given
compound could affect some of the events related to the
ligand/GR interaction and the consequent biological
response.
In the absence of hormone, GR is a 90-kDa heat shock
protein (hsp90)-regulated transcription factor primarily lo-
calized in the cytoplasm. Upon ligand binding, GR rapidly
translocates to the nucleus. The retrograde movement of the
GR throughout the cytoplasm seems to occur by cytoskeletal
tracks, cytoplasmic dynein being the motor protein used for
the movement (31). Also, the phosphorylation status of cy-
toplasmic steroid receptors seems to be relevant for the reg-
ulation of their nuclear import and further interaction with
the DNA (32–34). It is well known that the association of
hsp90 with the GR is a requirement to maintain the receptor
not only in its steroid binding conformation but also in a
transcriptional inactive state, even when the receptor is lo-
cated in the nucleus (35). Dissociation of hsp90 from the
receptor allows receptor binding to DNA and the subsequent
regulation of gene transcription (35). The transcriptional
specificity of GR is achieved by interaction of the P-box in the
first zinc finger of the DNA-binding domain of GR with a
palindromic GRE (36). This type of regulation has been iden-
tified in a large variety of genes, including some Bcl-2 family
proteins involved in the control of apoptosis, particularly the
bcl-X gene (37). GR activity is also regulated by factors
present in the promoter of the specific DNA sequences to
which GR binds (36).
The present paper analyzes the ability of MEL of regulat-
ing GR activation. It is described that the methoxyindole
prevents GR transformation in thymus by impairing hsp90
dissociation from the receptor and GR nuclear translocation.
Intriguingly, MEL was unable to modify GR activity in other
cell types such as L929 mouse fibroblasts, HC11 mouse mam-
mary epithelial cells, and Cos-7 cell line, suggesting that this
inhibitory effect on the GR is tissue specific.
Materials and Methods
Reagents and hormones
DEX, MEL, concanavalin A, and RPMI 1640 medium were purchased
from Sigma (St. Louis, MO). [3H]DEX (75 Ci/mmol) was supplied by
NEN Life Science Products (Boston, MA). Fetal calf serum (FCS) and
DMEM were provided by Invitrogen (Carlsbad, CA). Hormones were
dissolved in absolute ethanol and used at a final concentration of 10 nm.
A stock solution of concanavalin A was prepared in distilled water and
added to RPMI 1640 medium just before incubations. FCS was delipi-
dated with charcoal dextran as previously described (38).
Animals and thymocytes preparation
CF-1 male mice (21 d old) were housed in a standard animal room
with food and water ad libitum under controlled conditions of humidity
and temperature (21  2 C). Fluorescent lights were turned on auto-
matically every 12 h, from 0600 to 1800 h. All animals were treated and
cared in accordance with standard-international animal care protocols
(39). Mice were killed by cervical dislocation at fixed hours (between
1100 and 1200 h) to correct for diurnal variations in serum MEL levels.
Thymuses were immediately removed and extensively minced with
scissors in ice-cold RPMI 1640 medium. The cell suspension was filtered
through Nytex and viable cells were counted in a Neubauer hemocy-
tometer in the presence of 0.04% of Trypan-Blue.
In vitro incubation of thymocytes
Thymocytes (107 cells/well) were incubated in plastic dishes in 1 ml
RPMI 1640 medium containing 10% charcoal-stripped FCS, concanava-
lin A (2 g/ml), and 108 m DEX in the presence or absence of 108 m
MEL. The corresponding volume of ethanol (0.1%) was added to control
cells. Cells were incubated at 37 C for different times in a water bath
under a normal atmosphere. After incubation, cells were gently resus-
pended, placed in a 1.5 ml tube, and centrifuged at 2000 rpm for 5 min
at room temperature.
Competition assays
CF-1 male mice (21 d old) were adrenalectomized 48 h before ex-
periments and maintained on Purina chow (diet l), saline, and fresh
water ad libitum. Animals were killed by cervical dislocation. Thymuses
were used as a source of GR. Glands were homogenized with two
volumes of lysis buffer at pH 7.4 [10 mm HEPES, 5 mm EDTA, 20 mm
Na2MoO4, 10% glycerol, 0.1 mm phenylmethylsulfonyl fluoride (PMSF)]
and centrifuged at 15,000  g for 30 min at 4 C. Supernatants were
removed and referred to as cytosol. Protein concentration was quantified
according to Bradford (40). Five hundred microliters of cytosol (600 g
protein) were incubated during 16 h at 4 C with 5 nm [3H]DEX and either
5 m DEX or 5 m MEL. Bound hormone was separated by adsorption
with one volume of charcoal-dextran (2%:0.2%) in PBS (140 mm NaCl,
3 mm KCl, 1.5 mm KH2PO4, 16 mm NaH2PO4) followed by centrifugation
at 3000  g for 15 min. Bound radioactivity was determined in 400 l
supernatant.
Subcellular fractions separation
The 107 thymocytes were incubated for 30 min with or without DEX
in the presence or absence of 10 nm MEL. For subcellular fraction sep-
aration, cells were centrifuged for 5 min at 2000 rpm and washed with
ice-cold PBS buffer. Cells were then incubated in 200 l of hypotonic
buffer [10 mm Tris-HCl (pH 6.7); 0.2 mm MgCl2; 1 mm EGTA; 0.05 mm
leupeptin; 1 mm PMSF; 1 m pepstatin A] for 5 min on an ice-water bath
and lysed by douncing homogenization. Samples were centrifuged at
1500 rpm for 10 min at 4 C and supernatants were referred as cytoplas-
mic fraction. Pellets were washed twice in ice-cold PBS buffer, resus-
pended in 100 l of lysis buffer [20 mm Tris-HCl (pH 6.7); 70 mm NaCl;
10% glycerol; 1% Triton X-100; 0.5% Nonidet P-40; 300 U/ml DNase I
(Sigma); 0.05 mm leupeptin; 1 mm PMSF; 1 m pepstatin A], and incu-
bated on ice-water bath for 30 min. After the addition of 0.5 m NaCl, the
incubation was continued for additional 30 min. Samples were centri-
fuged at 12000 rpm for 5 min at 4 C, and supernatants were referred to
as nuclear fraction.
Confocal microscopy
For indirect immunofluorescence studies, 104 thymocytes or HC11
cells were incubated for 30 min at 37 C with either 10 nm DEX or 10 nm
MEL or both hormones together. Then a drop of the thymocytes sus-
pension was extended on a glass cover slide that was waved over a flame
for 5 sec. Thymocytes and HC11 cells were finally fixed with 4% para-
formaldehyde in PBS for 30 min at room temperature. Cells were per-
meabilized with 0.1% sodium dodecyl sulfate in PBS for 5 min and
washed three times with PBS. Cells were blocked in PBS containing 3%
BSA (PBS-BSA) for 30 min at room temperature and then incubated for
2 h at room temperature with an anti-GR antibody (BuGR2 clone, Af-
finity Bioreagents, Golden, CO) at 1:50 dilution in PBS-BSA. Cells were
washed with PBS-BSA and incubated for 30 min with Cy2-conjugated
secondary antibody antimouse IgG (492 nm excitation wavelength and
510 nm emission wavelength, catalog no. 711-225-152, Jackson Immu-
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noResearch, West Grove, PA) diluted 1:200 in PBS-BSA. Cells were
washed three times with PBS, incubated with 0.5 g/ml propidium
iodide for 5 min, and washed three times with PBS and once with
distilled water for 5 min. Finally, cells were mounted on a glass slide by
adding a drop of 50% glycerol in PBS. Fluorescence was detected with
a FV300 laser scanning microscope (Olympus America Inc., Melville,
NY) and images were analyzed with FluoView software (Olympus).
Coimmunoprecipitation
Cells (2  107) were incubated with or without DEX (10 nm) in the
presence or absence of MEL (10 nm) at 37 C. Forty-five minutes after
hormone addition, cells were centrifuged for 5 min at 2000 rpm and
washed once with cold PBS. Cells were lysed by adding 300 l of a buffer
of 10 mm HEPES (pH 7.5), 1 mm EDTA, 20 mm Na2MoO4, 1 mm EGTA,
0.05 mm leupeptin, 1 mm PMSF, and 1 m pepstatin A and homogenized
with a micropotter glass-Teflon. Cell extracts were centrifuged for 10
min at 13,000 rpm at 4 C. Two microliters of BuGR-2 anti-GR antibody
were added to 1 mg of proteins. Precipitation was performed by adding
30 l protein A/G plus agarose solution (Santa Cruz Biotechnology,
Santa Cruz, CA; catalog no. sc-2003; 2:1 suspended in buffer of 10 mm
HEPES (pH 7.5), 1 mm EDTA, 20 mm Na2MoO4, 1 mm EGTA, 0.05 mm
leupeptin, 1 mm PMSF, and 1 m pepstatin A). Samples were mixed by
rotation for 2 h at 4 C and centrifuged for 2 min at 13000 rpm. Pellets
were washed three times with TEGM buffer of 10 mm HEPES (pH 7.5),
1 mm EDTA, 20 mm Na2MoO4, 5% glycerol, and 50 mm NaCl and
centrifuged for 2 min at 13000 rpm. Proteins were resolved by Western
blotting.
Western blots
Samples from subcellular separation or coimmunoprecipitation as-
says were electrophoresed for 3 h at 100 V in a 12 or 9%, sodium dodecyl
sulfate-polyacrylamide gel, transferred to a polyvinyl difluoride mem-
brane (Bio-Rad Laboratories, Hercules, CA) by electroblotting in transfer
buffer containing 20% methanol (vol/vol), 0.19 m glycine, and 0.025 m
Tris-base (pH 8.3) at 300 mA for 1.5 h at 0 C. Blots were blocked 1 h at
room temperature in Tris-buffered saline [20 mm Tris-Cl (pH 7.5), 500
mm NaCl] containing low-fat powered milk (5%) and Tween 20 (0.1%).
The incubations with primary antibodies were performed at 4 C for 12 h
in blocking buffer (3% skim milk, 0.1% Tween 20, in Tris-buffered saline)
with the following antibody concentrations: 0.02% rabbit polyclonal
anti-hsp90 IgG (41) and 0.2% mouse monoclonal Bu-GR2. The mem-
branes were incubated with the corresponding counterantibody (0.03%
antirabbit IgG or 0.02% antimouse IgG; Bio-Rad) and the proteins ev-
idenced by enhanced chemiluminescence detection (GE Healthcare,
Buckinghamshire, UK). Densitometric analysis of protein levels was
performed with ImageQuant software (Molecular Dynamics, Inc.,
Sunnyvale, CA). The proper loading was evaluated by staining mem-
branes with Ponceau-S.
Cell culture and transient transfection assay
Cells were cultured at 37 C under humidified atmosphere with 5%
CO2 in p100 plates. Cos-7 and L-929 cells were grown in DMEM medium
and HC11 cells (kindly provided by Dr. Nancy Hynes, Basel, Switzer-
land) (42) in RPMI 1640 medium, both supplemented with 10% FCS
containing penicillin (100 IU/ml), streptomycin (100 g/ml), and glu-
tamine (2 mm). For transient transfections, 5  105 cells plated in 60-mm
plates were transfected with Lipofectin 2000 (Invitrogen) according to
the manufacturer’s instructions. Briefly, Cos-7 cells were cotransfected
with 3 g MMTV-luciferase vector (43) and 1 g pRSV-GR (44). pCMV-
LacZ (1 g) was used as a marker for transfection efficiency. Plasmids
were diluted in 100 l medium and added drop-wise to an equal volume
of medium containing 2 l Lipofectin 2000 (Invitrogen) for Cos-7 and
HC11 cells, and 4 l of the reagent for L929 cells. After 20 min, the
transfection mixture was added drop-wise to the cells and incubated
overnight at 37 C in 5% CO2 atmosphere. Then the serum-free medium
was replaced by regular medium supplemented with 10% charcoal-
stripped FCS and antibiotics. Cells were incubated with the correspond-
ing hormones during 48 h for Cos-7 cells and 24 h for HC11 and L929
cells. Luciferase activity was measured with a luciferase kit according to
the manufacturer’s protocol (catalog no. E1501; Promega Inc., Madison,
WI). -Galactosidase activity was measured as previously described
(45).
RNA analysis
RNA was extracted by the single-step method (46). For reverse tran-
scription, 4 g total RNA were used. The first cDNA strand was syn-
thesized with SuperScript reverse transcriptase (Life technologies) and
25 ng/l random primers (Invitrogen) as reverse complementary
primer. The oligonucleotides 5-CCGCAACAAGAAGCTCAG-
GAACTC-3 (MEL 1A forward) and 5-TCG TACTTGAGGCTGTG-
GCAAATG-3 (MEL 1A reverse) were used as forward and reverse
primers, respectively for Mel 1A receptor; the PCR amplified product is
248-bp length (47). For ROR receptor amplification, the oligonucleo-
tides 5-GCTGACGGAACTGCATGA-3 (RORa forward) and 5-TG-
GATATGTTCTGGGCAAGGT-3 (ROR reverse) were used as forward
and reverse primers, respectively. The PCR product is 280 bp length (48).
PCRs were normalized against actin expression. For that, RT-PCRs were
performed with the oligonucleotides 5-TCATGAAGTGTGACGTTGA-
CATCCGT-3 (ACTIN forward) and 5-CTTAGAAGCATTTGCGGTG-
CACGATG-3 (ACTIN reverse). The correspondent RT-PCR product is
280 bp length (Promega).
The cDNA pool (2 l), 1.25 U Thermus aquaticus Taq polymerase
(Invitrogen), and amplification primers (20 pmol each) in 25 l of PCR
mixture (2.5 l polymerase buffer, 4 mm MgCl2, 250 m each de-
oxynucleotide triphosphate) denatured 3 min at 96 C followed by 30 (for
actin) or 35 cycles (for Mel 1a and ROR) of amplification by using a step
program (1 min at 94 C, 1 min at 60 C, 1 min at 72 C) for Mel-1A; (1 min
at 94 C, 1 min at 57 C, 1 min at 72 C) for ROR; (40 sec at 94 C, 30 sec
at 70 C, 40 sec at 72 C) for actin; and a final extension at 72 C for 5 min.
PCR products were analyzed by electrophoresis in 1.5% agarose gels and
visualized under UV light.
Statistical analysis
Results were expressed as means  se or means  sd, as it is indicated
in the figure legends. In competition assays, a randomized block design
was used to minimize the variability between experiments. Two-way
ANOVAs followed by Tukey’s multiple comparisons tests were used to
detect significant differences among treatments and experiments. In
transfection assays, a generalized block design was used also to mini-
mize the variability between experiments, each experiment being con-
sidered one level of the experimental factor. Each experiment has two
independent replicates per treatment. Two-way ANOVA was also fol-
lowed by Tukey’s multiple comparisons. Statistical analyses were per-
formed with STATISTICA 6.0 (StatSoft, Inc., Tulsa, OK). Differences
were regarded as significant at P  0.05. Before statistical analysis data
were tested for normality and homoscedasticity using Lilliefors and
Bartlett’s tests, respectively. The interaction between experimental factor
and treatment factor was not significant in all the statistical analysis.
Results
As mentioned before, MEL prevents glucocorticoid-me-
diated apoptosis in certain cell types (3–7). These results
clearly pose an important question: in which step of the
molecular mechanism involved in GR action does the me-
thoxyindole impair the ability of activated GR to exert its
biological effects?
We first studied whether MEL is able to modulate DEX
binding to the GR. Figure 1 shows competition binding as-
says between DEX and MEL in GR-enriched thymus frac-
tions. MEL did not affect GR binding capacity, suggesting
that the methoxyindole should regulate some other down-
stream step of the GR activation pathway.
Confocal microscopy of immunofluorescence assays dem-
onstrate that inactivated GR was primarily localized in the
cytoplasm of thymocytes (Fig. 2, A–D). When cells were
incubated with DEX, GR rapidly translocated to the nucleus,
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as confirmed by its colocalization with the specific DNA dye
propidium iodide (Fig. 2, E–H). The ability of the ligand to
induce the translocation of GR to the nucleus was blocked by
MEL (Fig. 2, I–L). MEL did not affect per se the subcellular
localization of GR (Fig. 2, M–P). This observation was con-
firmed by subcellular fractionation followed by Western blot
assays. Figure 2Q shows that MEL inhibited DEX-mediated
GR nuclear translocation. DEX alone promoted GR translo-
cation into the nucleus with respect the untreated control,
whereas coincubation with steroid and MEL prevented the
GR translocation as shown by similar levels of GR with
respect to the control (Fig. 2Q).
To study a possible molecular mechanism for the antag-
onistic effect of MEL on GR biological effect, we performed
immunoprecipitation of GR, obtained from thymocytes in
primary culture, followed by Western blots against hsp90.
Figure 3 shows that after 45 min of treatment with DEX,
hsp90 is almost totally dissociated from GR heterocomplex
(Fig. 3, lane 2). Interestingly, the heat shock protein is re-
tained in the complex in the presence of MEL (Fig. 3, lane 3).
Incubation with MEL alone does not affect the heterocom-
plex composition (Fig. 3, lane 4). These results suggest that
the methoxyindole prevents GR transformation by blocking
the dissociation of hsp90.
To study whether the antagonistic effect of MEL on the GR
response is specific of thymocytes or it also occurs in other
cell types, a series of studies was performed. A pGR (codi-
fying for human GR) was cotransfected in Cos-7 cells with
pMMTV-Luc, which encodes for a luciferase reporter gene
FIG. 1. MEL does not affect binding of DEX to the GR. Competition
assay between DEX and MEL for the GR. An enriched thymic proteic
fraction of GR was obtained as described in Materials and Methods.
Six hundred micrograms of proteins were assayed for 16 h at 4 C with
3H DEX ([3H]Dex): 350,000 dpm (Ae  75 Ci/mmol) in the absence or
presence of 5 M DEX and 5 M MEL. Each treatment was done in
triplicate. Means  SD from a representative experiment (n  3) are
shown. *, P  0.05 ([3H]Dex  Dex vs. [3H]Dex and vs. [3H]Dex  Mel).
FIG. 2. MEL inhibits nuclear translocation of GR in mouse thymocytes. A–L, Fluorescence confocal microscopy. Primary thymocyte cultured
cells were incubated with ethanol (control) (A–D), 10 nM DEX alone (Dex) (E–H), or 10 nM MEL plus 10 nM DEX (Dex  Mel) (I–L) and with
10 nM Mel (M–P) for 30 min at 37 C as described in Materials and Methods. Then cells were immunolabeled for GR, treated with propidium
iodide to stain cells nucleus, and analyzed by laser fluorescence confocal microscopy as described in Materials and Methods. Each field was
independently visualized with the appropriate wavelength for propidium iodide (red; A, E, I, and M) and GR antibody plus Cy2 dye-conjugated
secondary antibody (green; B, F, J, and N), and then both images were merged (C, D, G, H, K, L, O, and P). Magnification: 1000 (A–C, I–K,
and M–O); 800 (E–G); 4000 (D, H, L, and P). Results are representative of three independent experiments. Q, Subcellular fractionation and
Western blot. Cells were incubated for 30 min at 37 C with or without Dex (10 nM) or Mel (10 nM). After incubation, a subcellular fractionation
protocol was performed as described in Materials and Methods to obtain the nuclear fractions (NF) and cytoplasmatic fractions (CF). Then
proteins were processed, and Western blot analysis was performed as described with a mouse monoclonal anti-GR (Q). Densitometric analysis
of protein levels was performed with Image Quant software. The proper loading was evaluated by staining the membranes with Ponceau-S.
Mean  SE values of GR levels (in arbitrary units) from three independent experiments are shown.
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under the control of the mouse mammary tumor virus pro-
moter with five GRE elements (43). Figure 4 shows that a
42.2  14.8-fold induction of luciferase activity was observed
in cells incubated with DEX (lane 2 vs. lane 1). Interestingly,
luciferase expression was not significantly different from
DEX-treated cells when MEL was coincubated with DEX.
(31.9  13.7-fold induction, lane 3), whereas the methoxy-
indole alone had no effect (1.2  0.1-fold induction, lane 4).
Therefore, at least in this cell type, MEL does not affect
GR-dependent expression.
As mentioned above, MEL effect could be elicited by its
interaction with membrane receptors like Mel 1a, or nuclear
receptors such as ROR. According to previous works, Cos-7
cells do not express those receptors (49, 50), so we decided
to test luciferase expression in cell types expressing both
receptors. Figure 5A shows that both GR-expressing cell
lines, HC11 and L929, express both Mel 1a and ROR re-
ceptors (Fig. 5A, lanes 3 and 4, respectively), comparable
with the expression observed in thymocytes (Fig. 5 A, lane
2).
As Fig. 5, B and C, shows, luciferase activity was induced
by DEX in both cell types (4.8  1.2 and 4.4  0.8-fold
induction with respect to the control) (Fig. 5, B and C, lane
2 vs. lane 1, respectively). Coincubation with MEL has no
effect respect to the DEX treatment (4.4  1.0 and 4.3 
0.5-fold induction vs. control, Fig. 5, B and C, lane 3, respec-
tively). Again, as in Cos-7 treatment, MEL alone was unable
to affect luciferase expression (0.8  0.1 and 1.1  0.2-fold
induction vs. control, Fig. 5, B and C, lane 4, respectively).
Therefore, no correlation exists between the presence of mel-
atonin receptors and the ability of MEL to inhibit GR-de-
pendent expression.
To confirm these results, confocal microscopy of immu-
nofluorescence analysis was also performed. Figure 5, D–G,
shows that the GR is localized in both the cytoplasm and
nucleus of untreated HC11 cells (Fig. 5D). When cells were
incubated with DEX, GR is mainly in the nucleus (Fig. 5E),
indicating that GR activation is hormone mediated. How-
ever, in contrast to those results observed with thymocytes,
the coincubation of DEX and MEL did not affect GR nuclear
localization induced by DEX (Fig. 5F). Again, MEL alone was
unable to affect the subcellular localization of GR (Fig. 5G).
Similar results were obtained with L929 fibroblast (data not
shown). Taken together, these results suggest a tissue-spe-
cific effect of MEL on the hormone-dependent GR activation.
Discussion
Recently our laboratory demonstrated that MEL, an in-
hibitor of the DEX-mediated apoptosis in thymocytes, in-
hibits both the glucocorticoid-induced cytochrome C release
and the increase in the levels of Bax protein and bax mRNA
(5). These results are partially in agreement with those pre-
viously reported by Sainz et al. (11), who showed that pre-
incubation with MEL for 3 h significantly decreases the per-
centage of DNA fragmentation in thymocytes from 25-d-old
rats further incubated for an additional 6-h period with DEX.
In our experimental conditions, the antiapoptotic effect of
MEL was evident when it was coincubated with DEX for only
3 h without preincubation. However, MEL did not affect the
levels of GR under these conditions (5). The antagonistic
effect between MEL and glucocorticoids was also reported
by Kiefer et al. (51) in MCF-7 cells. These authors (51) showed
that the methoxyindole can significantly diminish DEX-in-
duced GR transcriptional activation.
The mechanism of action of the GR involves a direct in-
teraction of a glucocorticoid ligand with the receptor. Once
FIG. 3. MEL prevents the dissociation of hsp90 from DEX-induced
GR in mouse thymocytes. A, Immunoadsorptions for GR-associated
hsp90. Primary thymocyte culture cells were incubated with or with-
out Dex (10 nM) or Mel (10 nM) for 45 min at 37 C. After cells were
washed, cytosols were prepared and analyzed for GR-associated
hsp90 as described in Materials and Methods. Immunoadsorptions
were performed with BuGR antibody (Ab) against GR or nonimmune
mouse IgG (). Western blotting was performed with antibodies
against GR and hsp90. Gels correspond to one representative exper-
iment. B, Mean  SE values of hsp90/GR levels (in arbitrary units)
from three independent experiments. Densitometric analysis of pro-
tein levels was performed with Image Quant software.
FIG. 4. MEL does not affect transcriptional activity of DEX-activated
GR in Cos-7 cells. Transcriptional activity assay of GR. COS-7 cells
were cotransfected with 1 g pRSV-GR and 3 g MMTV-Luc reporter
vector. One microgram of pCMV-LacZ vector were also introduced.
Cells were incubated for 48 h with ethanol (control; lane 1), 10 nM DEX
(lane 2), 10 nM DEX plus 10 nM Mel (lane 3), or 10 nM Mel (lane 4),
and luciferase activity was measured. After correcting for -galacto-
sidase activity, values were expressed as fold induction relative to the
controls. Means  SE from three independent experiments are shown.
Bars with different superscript letters are significantly different from
each other (P  0.05).
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the ligand/GR complex is formed, the precise conformation
adopted by the receptor is determined by the structure of a
given ligand (for a review see Ref. 52).
In this paper, we showed that in cytosolic fractions of
thymocytes, MEL is not able to compete with DEX for the
binding to the GR. However, we can neither dismiss the
possibility that the methoxyindole may compete with glu-
cocorticoids in vivo nor that MEL binds to the GR in a second
binding site different from the glucocorticoid binding pocket.
But if a second binding site would exist, MEL binding would
not affect the ability of the receptor to bind DEX. In this sense,
it has been suggested that the synthetic agonist 11,19-oxi-
doprogesterone binds to a second site in a closely related
member of the steroid receptor superfamily, the mineralo-
corticoid receptor (53). The biological effect of that steroid
seems to be mineralocorticoid receptor mediated through a
putative regulatory binding site that could be different from
the classical aldosterone-binding pocket (53). However, it
seems unlikely that a similar mechanism could take place
with the glucocorticoid receptor because the antagonistic
effect of MEL is not observed in other experimental models
such as Cos-7, HC11, and L929 cell lines, suggesting an in-
direct and thymocyte-specific action of the methoxyindole.
Thus, MEL would inhibit GR activity through the activation
of specific signal transduction pathways.
Several works have shown that the inhibitory effect of
MEL on GR activation involves the inhibition of GR inter-
action with specific GREs that are present in its target pro-
moters. However, those reports do not precisely account
which step between the ligand/GR complex formation and
the receptor/DNA interaction is affected by MEL. Actually,
most of those studies were limited to in vitro gel-shift assays
with nuclear extracts glucocorticoids-treated cells (30, 51, 54).
In this paper, we show that MEL does antagonize the glu-
cocorticoid response by preventing GR dissociation from the
hsp90-based heterocomplex and retaining the GR in the cy-
toplasm. At this point, it is still uncertain whether the tight
MEL-induced association of hsp90 to the GR is directly re-
sponsible for the cytoplasmic retention of the receptor or
whether MEL provokes the retention through an indirect
mechanism. Nonetheless, the final effect evoked by MEL is
the inhibition of the GR transformation. In this sense, it is
interesting to point out that the hsp90-immunophilin com-
plex associated to GR seems to be related to the transport of
FIG. 5. MEL affects neither transcriptional activity nor nuclear translocation of DEX-activated GR in cells expressing both Mel 1a and ROR
receptors. A, Expression of Mel-1a and ROR receptors. Total RNA from thymocytes, HC11, or L929 cells was extracted and RT-PCR with specific
primers for Mel-1a, ROR, and actin were performed as described in Materials and Methods. Lane 1, Negative control. B and C, Transcriptional
activity assay of GR. L-929 cells (B) or HC11 cells (C) were transfected with 3 g of MMTV-Luc reporter vector. One microgram of pCMV-LacZ
vector were also introduced. Cells were incubated for 24 h with ethanol (control; lane 1), 10 nM DEX (lane 2), 10 nM DEX plus 10 nM Mel (lane
3), or 10 nM Mel (lane 4), and luciferase activity was measured. After correcting for -galactosidase activity, values were expressed as fold
induction relative to controls. Means  SE from three independent experiments are shown. Bars with different superscript letters are significantly
different from each other (P  0.05). D–G, Fluorescence confocal microscopy. HC11 cells were incubated for 30 min with control (D), Dex (10
nM) (E), Dex  Mel (10 nM) (F), or Mel (10 nM) (G). Then cells were immunolabeled for GR and analyzed by laser fluorescence confocal microscopy
as described in Materials and Methods. Magnification: 400. Bar, 50 m. Results are representative of three independent experiments.
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the receptor throughout the cytoplasm (55). When the het-
erocomplex is disrupted, the GR nuclear translocation is
impaired, even though the chaperone complex is still asso-
ciated with the receptor (31). Therefore, it might be possible
that MEL plays a similar role in preventing the retrograde
transport of the GR.
The inhibition of GR nuclear translocation by the activa-
tion of a given pathway was also suggested by Goleva et al.
(56), who demonstrated that a GR signal transducer and
activator of transcription-5 heterodimer prevents the nuclear
import of GR, suggesting a novel role for signal transducer
and activator of transcription-5 in IL-2-induced steroid in-
sensitivity (56).
Because the inhibitory effect of MEL was not observed in
other cell types such as HC11 and L929 cells, it is possible to
speculate that MEL could not bind directly to any of the
proteins of the GR/hsp 90 heterocomplex, but it activates
some tissue-specific pathway that leads to GR nuclear trans-
location blockage; for example, MEL might affect the GR
phosphorylation state, which plays a key role in GR subcel-
lular destination (57). Recently it was demonstrated in hu-
man T cells that phosphorylation of GR by ERK1/2 inhibits
DEX-mediated GR nuclear localization (58).
On the other hand, it was also demonstrated that MEL
antagonize the Ca2 binding protein calmodulin (CaM)
through a direct interaction of the methoxyindole with the
CaM -subunit (59, 60). As it was suggested, CaM could be
involved in the modulation of GR functions through its in-
teraction with the GR-associated hsp90 (59, 61), allowing the
speculation that CaM would participate in the MEL/GR
antagonism. However, this putative mechanism, involving a
direct interaction Mel/CaM, would not explain the tissue-
specific effects that we describe here.
In the thymus, two types of MEL receptors are expressed.
Mel 1 membrane receptors that have been described in rat T
and B lymphocytes (18) and the nuclear receptors RZR/
ROR, ROR, and RZR (18, 20).
The activation of Mel 1a by MEL decreases cAMP accu-
mulation in mouse thymocytes (19). However, because DEX
also decreases cAMP levels in thymocytes, this pathway does
not seem to be involved in the inhibitory effect exerted by
MEL (5). In addition, activation of Mel 1a also regulates the
level of other second messengers such as cGMP (19, 62) and
cytosolic Ca2 (16). Thus, we cannot discard the possibility
that some of them could be involved in the effect of MEL.
On the other hand, as mentioned above, MEL binds to
purified thymocyte nuclei (29), suggesting the existence of
functional nuclear receptors of the ROR family. In other
tissues MEL regulates the expression of several genes
through that receptor (27, 28). Therefore, the ROR/MEL
complex could be also a possible candidate to account for the
inhibition of the DEX-GR complex translocation to the nu-
cleus. In addition, a relationship between GR and ROR has
been suggested because the GR-interacting protein-1 func-
tions as a coactivator for the ROR receptor (63).
Thus, we speculate which signaling pathway would me-
diate the inhibitory effect between MEL and GR. In this sense,
several reports pointed out the membrane receptor Mel 1a as
a putative candidate (30). In fact, it was demonstrated in
MCF7 cells that the action of MEL seems to be sensitive to
pertussis toxin, indicating a possible involvement of Gi pro-
tein coupled to Mel 1a (51).
Our results show that despite both receptors, Mel1a and
ROR, are expressed in HC11 and L929 cell lines, melatonin
is unable to antagonize GR nuclear translocation. Further-
more, this absence of correlation between the presence of
melatonin receptors and the ability of MEL to inhibit GR-
dependent expression suggests that the tissue specificity for
this effect would be on one hand, independent of the mel-
atonin receptors or, on the other hand, owing to tissue spe-
cific factors acting downstream the receptors, in the signal
transduction pathway.
In summary, the present work shows for the first time the
molecular mechanism involving the GR/MEL antagonism
by which this methoxyindole inhibits GR nuclear transloca-
tion and hsp90 dissociation. The apparent tissue specificity
for this mechanism is a matter of further studies.
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